BofA cuts Dentsply Sirona stock price target on guidance reset
BofA Securities reduced its price target for Dentsply Sirona (XRAY) to $14 from $17, citing disappointing Q3 results and a revised 2026 EPS guidance of $1.10. The stock trades near its 52-week low at $8.14. BofA noted positive developments in some segments but expects growth stabilization over time. XRAY's Q3 earnings and revenue missed estimates, leading to a stock price drop.
How this was made
The 30-second read
Why it matters
The downgrade reflects concerns over slower growth in key product lines, but highlights areas of strength that may support a rebound.
Market read
Analyst target reduction after earnings miss is likely to drive short‑term downside for XRAY.
What to watch
Potential upside from recovery in U.S. endodontics and double‑digit growth in market‑integrated solutions could mitigate short‑term weakness.
Background
Dentsply Sirona reported Q3 2026 results that missed EPS and revenue expectations, prompting BofA to adjust its valuation.
Ticker impact
BofA lowered its price target for Dentsply Sirona to $14 and highlighted a Q3 earnings miss and reduced 2026 EPS guidance.
downward pressure as the market prices in the guidance cut and earnings shortfall
The target reduction and missed EPS indicate weaker near‑term earnings outlook, likely prompting sellers.
Market effects
Dental equipment sector may face broader scrutiny as Dentsply's guidance reset signals slower demand.
U.S. healthcare equipment stocks could see modest pullback.
Limited to investors focused on U.S. med‑tech and dental device space.
Counterpoint
The price target cut may overstate downside if the company’s long‑term growth initiatives in connected technology and orthodontics bear fruit.
Key entities
- companyDentsply Sirona
Dental equipment manufacturer (NASDAQ: XRAY).
- analystBofA Securities
Investment bank that issued the price‑target cut.
